Annexon (ANNX) announced that it has commenced an underwritten public offering of $75M of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Annexon. Goldman Sachs & Co., TD Cowen and Wells Fargo Securities are acting as joint book-running managers for the proposed offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon Biosciences: Promising Advancements in Late-Stage Complement Inhibitors Drive Buy Rating
- Positive Investment Outlook for Annexon Biosciences Driven by Financial Stability and Key Pipeline Developments
- Annexon Biosciences Reports Increased R&D Expenses
- Annexon reports Q3 EPS (37c), consensus (34c)
- ANNX Upcoming Earnings Report: What to Expect?